# Johnson & Johnson (jnj)

Generated: `2026-02-04T21:41:53Z`

- Assets: **44**
- Assets with linked trials: **20**
- Trials: **263**

## Top assets

| Asset | Highest stage | Linked trials | Example indications |
|---|---:|---:|---|
| Azacitidine | Registration | 5 | Cancer (ATLAS) intravesical delivery system) Invasive Bladder Cancer BCG |
| ypertension75mg | Registration | 0 | pipeline is based on the current status of these this information. *AC Immune ACI-35.030. of rilpivirine and cabotegravir: ViiV Healthcare; Tau Immunotherapy: AC Immune SA; Biotech; AKEEGA: TESARO, an oncology- iPSC-derived chimeric antigen receptor |
| (PROTOSTAR) | Registration | 0 | Arthritis Hemolytic Anemia (ENERGY) Alloimmune Thrombocytopenia |
| (ORIGAMI-2) | Registration | 0 | Multiple Myeloma CD38 exposed |
| (MajesTEC-4) | Registration | 0 | Acute Myeloid Leukemia (cAMeLot- |
| TREMFYA | Phase 3 | 29 | Ulcerative Colitis; Pediatric Ulcerative |
| ERLEADA | Phase 3 | 24 | ASCT Localized Prostate |
| nipocalimab | Phase 3 | 11 | Hemolytic Disease; Warm Autoimmune |
| TALVEY + TECVAYLI | Phase 3 | 7 | Relapsed Refractory; Relapsed Refractory (MonumenTAL-6) |
| icotrokinra | Phase 3 | 4 | Psoriatic Arthritis; Crohn's Disease (ICONIC-CD) |
| bleximenib | Phase 3 | 4 | Relapsed Refractory 1) |
| RYBREVANT | Phase 3 | 4 | Frontline Non Small; Colorectal Cancer |
| SPRAVATO | Phase 3 | 3 | Major Depressive Disorder Pediatrics |
| JNJ-7446 | Phase 3 | 2 | Lung Cancer |
| INLEXZO (gemcitabine | Phase 3 | 2 | Non Muscle Invasive; High Risk High Risk Non Muscle |
| SIRTURO | Phase 3 | 0 | L e p r o s y under review by regulatory bodies. Inclusion in the & Johnson assumes no obligation to update Long acting HIV injectible treatment regimen; L e p r o s y under review by regulatory bodies. |
| Leprosy | Phase 3 | 0 | under review by regulatory bodies. |
| JNJ-4804 Co-antibody | Phase 3 | 0 | Psoriatic Arthritis; Crohn's Disease |
| JNJ-4681 | Phase 3 | 0 | Hematological Malignancies |
| JNJ-3413 | Phase 3 | 0 | Lymphoma |
| JNJ-2175 | Phase 3 | 0 | Solid Tumors |
| JNJ-1887 sCD59 | Phase 3 | 0 | Geographic Atrophy |
| ITI-1284 | Phase 3 | 0 | Alzheimer's Disease-Related; with Generalized Anxiety |
| Bleximenib | Phase 3 | 0 | Newly Diagnosed AML, with Venetoclax and |
| (amivantamab) | Phase 2 | 27 | Cancer (ORIGAMI-5) |